Patents by Inventor Pierre Saint-Mezard

Pierre Saint-Mezard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALLOSTERIC AKT INHIBITORS FOR USE IN THE TREATMENT OF HEREDITARY HEMORRHAGIC TELANGIECTASIA
    Publication number: 20240092801
    Abstract: The present invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, for use in the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
    Type: Application
    Filed: September 29, 2021
    Publication date: March 21, 2024
    Inventors: Damien PICARD, Pierre SAINT-MEZARD
  • METHODS OF USING CADHERIN 11 (CDH11) ANTAGONISTS
    Publication number: 20100322926
    Abstract: The present invention provides novel methods of inhibiting or preventing epithelial-mesenchymal transition (EMT) or endothelial-mesenchymal transition (EnMT), such as EMT or EnMT, associated with fibrosis and chronic tissue rejection. The present invention also provides methods for diagnosing or assessing whether a subject has or is at risk of developing a disease associated with CDH11 expression, as well as methods for determining the prognosis of a subject diagnosed with a CDH11-associated condition. The invention employs CDH11 antagonists to downmodulate CDH11 activity, thereby inhibiting EMT or EnMT.
    Type: Application
    Filed: February 9, 2009
    Publication date: December 23, 2010
    Applicant: Novartis AG
    Inventor: Pierre Saint-Mezard
  • Methods and compositions for assessing acute rejection
    Patent number: 7811767
    Abstract: The invention relates to the analysis and identification of genes that are up-regulated simultaneously in transplant rejection. This simultaneous up-regulation of genes provides a molecular signature to accurately detect transplant rejection.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: October 12, 2010
    Assignee: Novartis AG
    Inventors: Friedrich Raulf, Pierre Saint-Mezard, Hai Zhang
  • TRANSPLANT REJECTION MARKERS
    Publication number: 20100233716
    Abstract: The invention relates to the analysis and identification of genes that are regulated simultaneously in chronic kidney transplant rejection. This simultaneous regulation of genes provides a molecular signature to accurately detect, and optionally classify, chronic kidney transplant rejection.
    Type: Application
    Filed: November 6, 2008
    Publication date: September 16, 2010
    Inventors: Pierre Saint-Mezard, Hai Zhang
  • METHODS AND COMPOSITIONS FOR ASSESSING ACUTE REJECTION
    Publication number: 20090022730
    Abstract: The invention relates to the analysis and identification of genes that are up-regulated simultaneously in transplant rejection. This simultaneous up-regulation of genes provides a molecular signature to accurately detect transplant rejection.
    Type: Application
    Filed: March 13, 2007
    Publication date: January 22, 2009
    Inventors: Friedrich Raulf, Pierre Saint-Mezard, Hai Zhang